16:10:36 Europe / Stockholm

Prenumeration

2022-08-19 09:17:00

Redeye returns with a more detailed take on the Q2 report and concludes that the slow sales ramp-up is likely to spill over onto next year, by when FDA approval should be in place, opening the door for more substantial long-term sales growth. We also expect an equity issue by late H1 2023 rather than late 2023/early 2024 and have adjusted our fair value range according to our capital raise assumptions.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/